Pre-made Glofitamab biosimilar (Bispecific mAb with Domain Crossover, anti-CD3E;MS4A1/CD20 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-248

Pre-made Glofitamab biosimilar (Bispecific mAb with Domain Crossover, anti-CD3E;MS4A1/CD20 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-248-1mg 1mg Inquiry
GMP-Bios-ab-248-10mg 10mg Inquiry
GMP-Bios-ab-248-100mg 100mg Inquiry
GMP-Bios-ab-248-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Glofitamab biosimilar, Bispecific mAb with Domain Crossover, Anti-CD3E;MS4A1/CD20 antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7therapeutic antibody
INN Name Glofitamab
TargetCD3E;CD20
FormatBispecific mAb with Domain Crossover
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda;Kappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone;3pp3:HL/3pp4:HL
99% SI StructureNone;6y9a:HL
95-98% SI StructureNone;6y97:HL
Year Proposed2019
Year Recommended2020
CompaniesRoche
Conditions Approvedna
Conditions ActiveDiffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma
Conditions Discontinuedna
Development Techna